Search
Debamestrocel
go.drugbank.com/drugs/DB17934InvestigationalDebamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]
HNF4α srRNA
go.drugbank.com/drugs/DB27228InvestigationalHNF4α srRNA is a biologic drug. … HNF4α srRNA is under investigation in clinical trial NCT06583993 (A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients).
Rizedisben
go.drugbank.com/drugs/DB21610InvestigationalRizedisben is a small molecule drug. Rizedisben is under investigation in clinical trial NCT04983862 (Fluorescent Imaging of Nerves with Illuminare-1 During Surgery).
Certociclib
go.drugbank.com/drugs/DB21736InvestigationalCertociclib is a small molecule drug. Certociclib is under investigation in clinical trial NCT05252416 ((VELA) Study of BLU-222 in Advanced Solid Tumors).
Oral Polio Vaccine
go.drugbank.com/drugs/DB15864InvestigationalThe polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are … The vaccine is created by weakening the wildtype before being placed into the oral vaccine.
Talopram
go.drugbank.com/drugs/DB09190ExperimentalTalopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalMRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
LuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
IO-202
go.drugbank.com/drugs/DB17548InvestigationalIO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4).[A257276] It is being investigated in cancers.